| Literature DB >> 35936155 |
Salem M Bazarah1, Ruba M Alotaibi2, Rozan A Alghamdi2, Abdullah S Waheeb2, Wareef A Rafeea2, Sedrah K Talab2, Hassan M Badawoud2.
Abstract
BACKGROUND: Helicobacter pylori (H. pylori) infection and gastroesophageal reflux disease (GERD) are widely spread clinical terms. GERD refers to the backflow of gastric acid to the esophagus and upper gastrointestinal tract, causing irritation. H. pylori is a gram-negative bacillus that adheres mainly to the gastric mucosa, causing peptic ulcers and gastritis. The nature of the relationship between GERD and H. pylori is yet to be explored, and few studies have been conducted. In contrast, some studies suggest a protective role of H. pylori against GERD. This study aimed to identify the demographic, clinical, and endoscopic findings of patients with GERD who underwent H. pylori testing.Entities:
Keywords: atrophic gastritis; clo test; gastritis; gastroesophageal reflux disease (gerd); helicobacter pylori eradication; helicobacter pylori
Year: 2022 PMID: 35936155 PMCID: PMC9348513 DOI: 10.7759/cureus.26542
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Baseline characteristics of studied patients
ASA: acetylsalicylic acid; NSAIDs: nonsteroidal anti-inflammatory drugs; PPIs: proton pump inhibitors.
| Variable | Value (n = 255) | Percentages |
| Age | 45.51 ± 15.312 | |
| Male | 108 | 42.4% |
| Female | 147 | 57.6% |
| Saudi | 191 | 74.9% |
| Non-Saudi | 64 | 25.1% |
| Smokers | 11 | 4.3% |
| Comorbidities | 89 | 34.9% |
| NSAIDs/ASA | 87 | 34.1% |
| PPI | 210 | 82.4% |
| BMI | 28.36 ± 7.58 |
Bivariate statistics for demographic parameters
ASA: acetylsalicylic acid; NSAIDs: nonsteroidal anti-inflammatory drugs; PPIs: proton pump inhibitors.
| Variables | Positive | Negative | P-value |
| Age | 16.46 ± 16.46 | 45.50 ± 15.11 | 0.827 |
| BMI | 27.78 ± 6.32 | 28.68 ± 8.19 | 0.33 |
| Male, n = 108 | 36 (33.3%) | 72 (66.7%) | 0.668 |
| Female, n = 147 | 54 (60%) | 93 (56.3%) | 0.668 |
| Saudi | 68 (75.6%) | 123 (74.5%) | 0.777 |
| Non-Saudi | 22 (24.4%) | 42 (25.5%) | 0.777 |
| Smoking status, n = 11 | 3 (27.3%) | 11 (72.7%) | 0.751 |
| Comorbidities, n = 89 | 26 (29.2%) | 63 (70.8%) | 0.359 |
| PPI, n = 210 | 76 (36.2%) | 134 (63.8%) | 0.635 |
| NSAIDs/ASA, n = 87 | 32 (36.8%) | 55 (63.2%) | 0.826 |
Bivariate statistics for clinical parameters
ASA: acetylsalicylic acid; NSAIDs: nonsteroidal anti-inflammatory drugs; PPIs: proton pump inhibitors.
| Variables | Positive | Negative | P-value |
| Abdominal pain, n = 126 | 40 (31.7%) | 86 (68.3%) | 0.298 |
| Fever, n = 6 | 1 (16.7%) | 5 (83.3%) | 0.429 |
| Regurgitation, n = 73 | 24 (32.9%) | 49 (67.1%) | 0.714 |
| Heartburn, n = 92 | 32 (34.8%) | 60 (65.2%) | 1 |
| Chest pain, n = 25 | 10 (40%) | 15 (60%) | 0.766 |
| Nausea, n = 51 | 15 (29.4%) | 36 (70.6%) | 0.413 |
| Loss of appetite, n = 6 | 2 (33.3%) | 4 (66.7%) | 1 |
| Bloating, n = 38 | 14 (36.8%) | 24 (63.2%) | 0.974 |
| Weight loss, n = 10 | 4 (40%) | 6 (60%) | 0.745 |
| Chronic cough, n = 12 | 3 (25%) | 9 (75%) | 0.548 |
| Endoscopic and pharmacologic | |||
| Gastritis, n = 132 | 53 (40.2%) | 79 (59.8%) | 0.121 |
| Esophagitis, n = 62 | 23 (37.1%) | 39 (62.9%) | 0.85 |
| Hiatal hernia, n = 71 | 22 (30.98%) | 49 (69.0%) | 0.454 |
| Drug use | |||
| PPI, n = 210 | 76 (36.2%) | 134 (63.8%) | 0.635 |
| NSAIDs/ASA, n = 87 | 32 (36.8%) | 55 (63.2%) | 0.826 |